The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial EUROPEAN RADIOLOGY Jamshidi, N., Jonasch, E., Zapala, M., Korn, R. L., Brooks, J. D., Ljungberg, B., Kuo, M. D. 2016; 26 (8): 2798-2807


To characterize a radiogenomic risk score (RRS), a previously defined biomarker, and to evaluate its potential for stratifying radiological progression-free survival (rPFS) in patients with metastatic renal cell carcinoma (mRCC) undergoing pre-surgical treatment with bevacizumab.In this IRB-approved study, prospective imaging analysis of the RRS was performed on phase II clinical trial data of mRCC patients (n?=?41) evaluating whether patient stratification according to the RRS resulted in groups more or less likely to have a rPFS to pre-surgical bevacizumab prior to cytoreductive nephrectomy. Survival times of RRS subgroups were analyzed using Kaplan-Meier survival analysis.The RRS is enriched in diverse molecular processes including drug response, stress response, protein kinase regulation, and signal transduction pathways (P? 25 months (P?=?0.005) and overall survival of 25 versus >37 months in the high and low RRS groups (P?=?0.03), respectively. Conventional prognostic predictors including the Motzer and Heng criteria were not predictive in this cohort (P?>?0.05).The RRS stratifies rPFS to bevacizumab in patients from a phase II clinical trial with mRCC undergoing cytoreductive nephrectomy and pre-surgical bevacizumab.• The RRS SOMA stratifies patient outcomes in a phase II clinical trial. • RRS stratifies subjects into prognostic groups in a discrete or continuous fashion. • RRS is biologically enriched in diverse processes including drug response programs.

View details for DOI 10.1007/s00330-015-4082-8

View details for Web of Science ID 000379192500043

View details for PubMedID 26560727